Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, tolerabilit...
Cantor Fitzgerald analyst Charles Duncan reiterates Cytokinetics (NASDAQ:CYTK) with a Overweight.
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $90 price ta...
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced two presentations at the 2024 American College of Clinical Pharmacolog...
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $65 t...
JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:CYTK) with a Market Outperform and maintains $78 price t...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $90 price ta...
Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $72 price target.
